VEZT抗体;VEZT Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P12897(VEZT Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

VEZT (Vezatin), an integral membrane protein, is encoded by the *VEZT* gene and is primarily associated with cell-cell adhesion and cytoskeletal organization. It localizes to adherens junctions, where it interacts with myosin VIIA and other proteins to stabilize epithelial structures and regulate cell polarity. Initially identified in studies of Usher syndrome (a genetic disorder affecting hearing and vision), VEZT's role expanded with discoveries linking it to cancer progression. Research shows VEZT is frequently downregulated in malignancies like gastric, breast, and colorectal cancers, correlating with poor prognosis, metastasis, and epithelial-mesenchymal transition (EMT). Its loss may disrupt cell adhesion, promoting invasive behavior.

VEZT antibodies are critical tools for investigating these mechanisms. They enable detection of VEZT expression in tissues or cell lines via techniques like immunohistochemistry, Western blotting, and immunofluorescence. Commercially available polyclonal or monoclonal antibodies target specific epitopes, aiding in studies of VEZT's interaction networks and signaling pathways. Recent efforts focus on validating VEZT as a potential biomarker for cancer diagnosis or therapeutic targeting. However, challenges remain in standardizing antibody specificity across experimental models. Ongoing research aims to clarify VEZT's dual roles in homeostasis and disease, leveraging these antibodies to explore its therapeutic potential in oncology and genetic disorders.